These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19968072)

  • 1. [Efficacy and safety of high-dose dexamethasone-based regimens in the newly diagnosed multiple myeloma patients with renal impairment].
    Li J; Zhou DB; Jiao L; Duan MH; Zhang W; Zhao YQ; Shen T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):567-9. PubMed ID: 19968072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.
    Li J; Zhou DB; Jiao L; Duan MH; Zhang W; Zhao YQ; Shen T
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):394-8. PubMed ID: 19858061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
    Tosi P; Zamagni E; Tacchetti P; Ceccolini M; Perrone G; Brioli A; Pallotti MC; Pantani L; Petrucci A; Baccarani M; Cavo M
    Biol Blood Marrow Transplant; 2010 Aug; 16(8):1115-21. PubMed ID: 20197100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma].
    Li J; Zhao Y; Luo SK; Huang BH; Ding Y; Tong XZ; Wang HH; Zheng D; Su C; Peng AH
    Ai Zheng; 2008 Apr; 27(4):429-34. PubMed ID: 18423132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
    Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
    Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
    Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
    Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
    Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
    Oehrlein K; Langer C; Sturm I; Pönisch W; Hahn-Ast C; Kuhn S; Weisel KC
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):191-6. PubMed ID: 22341857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
    Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
    J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
    Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
    J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
    Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
    Dimopoulos MA; Richardson PG; Schlag R; Khuageva NK; Shpilberg O; Kastritis E; Kropff M; Petrucci MT; Delforge M; Alexeeva J; Schots R; Masszi T; Mateos MV; Deraedt W; Liu K; Cakana A; van de Velde H; San Miguel JF
    J Clin Oncol; 2009 Dec; 27(36):6086-93. PubMed ID: 19858394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
    Fukushima T; Nakamura T; Iwao H; Nakajima A; Miki M; Sato T; Sakai T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Nakajima H; Motoo Y; Umehara H
    Anticancer Res; 2011 Jun; 31(6):2297-302. PubMed ID: 21737655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
    Nozza A; Siracusano L; Armando S
    Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange.
    Costa LJ; Abbas J; Ortiz-Cruz KL; Kang Y; Stuart RK
    Eur J Haematol; 2012 Nov; 89(5):432-4. PubMed ID: 22971164
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
    J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination of bortezomib and dexamethasone for newly diagnosed multiple myeloma].
    Li J; Zeng LJ; Zhao Y; Su C; Huang BH
    Zhonghua Xue Ye Xue Za Zhi; 2009 Aug; 30(8):543-7. PubMed ID: 19954643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.